Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 143

Related Citations for PubMed (Select 16319406)

1.

Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol.

Zipursky RB, Gu H, Green AI, Perkins DO, Tohen MF, McEvoy JP, Strakowski SM, Sharma T, Kahn RS, Gur RE, Tollefson GD, Lieberman JA.

Br J Psychiatry. 2005 Dec;187:537-43.

2.
3.

Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.

Kinon BJ, Basson BR, Gilmore JA, Tollefson GD.

J Clin Psychiatry. 2001 Feb;62(2):92-100.

PMID:
11247108
4.

A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.

Perez-Iglesias R, Crespo-Facorro B, Amado JA, Garcia-Unzueta MT, Ramirez-Bonilla ML, Gonzalez-Blanch C, Martinez-Garcia O, Vazquez-Barquero JL.

J Clin Psychiatry. 2007 Nov;68(11):1733-40.

PMID:
18052567
6.

The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study.

Poyurovsky M, Tal V, Maayan R, Gil-Ad I, Fuchs C, Weizman A.

Eur Neuropsychopharmacol. 2004 Aug;14(4):332-6.

PMID:
15163444
7.

Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population.

Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O, Ramirez-Bonilla ML, Alvarez-Jimenez M, Pelayo-Teran JM, Garcia-Unzueta MT, Amado JA, Vazquez-Barquero JL.

Schizophr Res. 2008 Feb;99(1-3):13-22. Epub 2007 Dec 3.

PMID:
18053689
8.

[Prescription of olanzapine in children and adolescent psychiatric patients].

Frémaux T, Reymann JM, Chevreuil C, Bentué-Ferrer D.

Encephale. 2007 Mar-Apr;33(2):188-96. Review. French.

PMID:
17675914
9.

Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study.

Poyurovsky M, Fuchs C, Pashinian A, Levi A, Faragian S, Maayan R, Gil-Ad I.

Psychopharmacology (Berl). 2007 Jun;192(3):441-8. Epub 2007 Feb 20.

PMID:
17310385
10.

Olanzapine and haloperidol in first episode psychosis: two-year data.

Green AI, Lieberman JA, Hamer RM, Glick ID, Gur RE, Kahn RS, McEvoy JP, Perkins DO, Rothschild AJ, Sharma T, Tohen MF, Woolson S, Zipursky RB; HGDH Study Group.

Schizophr Res. 2006 Sep;86(1-3):234-43. Epub 2006 Aug 2.

PMID:
16887334
11.

Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.

Wu RR, Zhao JP, Guo XF, He YQ, Fang MS, Guo WB, Chen JD, Li LH.

Am J Psychiatry. 2008 Mar;165(3):352-8. doi: 10.1176/appi.ajp.2007.07010079. Epub 2008 Feb 1.

PMID:
18245179
12.

Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol.

Krakowski M, Czobor P, Citrome L.

Schizophr Res. 2009 May;110(1-3):95-102. doi: 10.1016/j.schres.2009.02.006. Epub 2009 Mar 9.

PMID:
19269139
13.

Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study.

Poyurovsky M, Isaacs I, Fuchs C, Schneidman M, Faragian S, Weizman R, Weizman A.

Am J Psychiatry. 2003 Feb;160(2):297-302.

PMID:
12562576
14.

Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study.

Ujike H, Nomura A, Morita Y, Morio A, Okahisa Y, Kotaka T, Kodama M, Ishihara T, Kuroda S.

J Clin Psychiatry. 2008 Sep;69(9):1416-22.

PMID:
19193342
15.

A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms.

Kinon BJ, Lipkovich I, Edwards SB, Adams DH, Ascher-Svanum H, Siris SG.

J Clin Psychopharmacol. 2006 Apr;26(2):157-62.

PMID:
16633144
16.

Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis.

Zipursky RB, Christensen BK, Daskalakis Z, Epstein I, Roy P, Furimsky I, Sanger T, Kapur S.

Can J Psychiatry. 2005 Jul;50(8):462-9.

PMID:
16127964
17.

Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol.

Peuskens J, Gillain B, De Graeve D, Van Vleymen B, Albert A.

Eur Psychiatry. 2009 Apr;24(3):154-63. doi: 10.1016/j.eurpsy.2008.11.002. Epub 2008 Dec 31.

PMID:
19118983
18.

Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.

Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.

Clin Ther. 2008 Dec;30(12):2378-86. doi: 10.1016/j.clinthera.2008.12.020.

PMID:
19167596
19.

Weight effects associated with antipsychotics: a comprehensive database analysis.

Parsons B, Allison DB, Loebel A, Williams K, Giller E, Romano S, Siu C.

Schizophr Res. 2009 May;110(1-3):103-10. doi: 10.1016/j.schres.2008.09.025. Epub 2009 Mar 24.

PMID:
19321312
20.

Amantadine for weight gain associated with olanzapine treatment.

Deberdt W, Winokur A, Cavazzoni PA, Trzaskoma QN, Carlson CD, Bymaster FP, Wiener K, Floris M, Breier A.

Eur Neuropsychopharmacol. 2005 Jan;15(1):13-21.

PMID:
15572269
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk